[Successful treatment with caspofungin of an invasive candidosis resistant to liposomal amphotericin B in a neutropenic patient].
Rome
A
A
André
N
N
Michel
A
A
Coze
C
C
Gentet
J-C
JC
Bernard
J-L
JL
D000666:Amphotericin B / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000628:therapy; D002175:Candida / Q000187:drug effects*; D002176:Candida albicans / Q000187:drug effects; D041221:Candida glabrata / Q000187:drug effects; D002177:Candidiasis / Q000150:complications / Q000188:drug therapy*; D000077336:Caspofungin; D002675:Child, Preschool; D025141:Drug Resistance, Fungal / Q000187:drug effects*; D054714:Echinocandins; D006801:Humans; D016867:Immunocompromised Host; D055666:Lipopeptides; D008297:Male; D017599:Neuroectodermal Tumors / Q000628:therapy; D009503:Neutropenia / Q000150:complications*; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; C068538:liposomal amphotericin B; D000666:Amphotericin B; D000077336:Caspofungin